Science & Innovation Theaters provide a structured focus for participants to gain information on specific products, therapeutic areas, and/or disease states in presentations provided by company designated presenters.
Materials presented in theaters may be promotional and concentrate on a specific product, service, or therapeutic area. Therefore, these presentations are considered promotional and do not offer continuing education credit.
Science & Innovation Theater presentations are scheduled during AMCP 2021 Virtual on Thursday, April 15 from 10-10:30am and 2-2:30pm.
Thursday, April 15 | 10-10:30am
The Power of Microbiome – Can it be unlocked to break the cycle of recurrent Clostridioides difficile infection?
Sponsored by Ferring Pharmaceuticals Inc.
Program Educational Objectives:
- Understand the role of the microbiome in overall health
- Explore the relationship between the gut microbiome and Clostridioides difficile infection (CDI)
- Review the risk factors and pathobiology of CDI
- Assess the current burden of CDI and recurrent infection
- Evaluate the current management of CDI and the potential of microbiome-based therapeutics
Paul Feuerstadt, MD, FACG, Assistant Clinical Professor of Medicine, Yale University School of Medicine
Thursday, April 15 | 2-2:30pm
Tech-Enabled Pharmacy Services: Improving Medication Use among Complex & Vulnerable Medicare Members
Sponsored by RxAnte
Join RxAnte, a leading analytics and clinical services company, for a discussion on how a technology-enabled pharmacy service intervention can impact quality measure performance and medical utilization in complex and vulnerable Medicare members.
In a session led by Chris Bane, VP of Business Development and Marketing at RxAnte, and Sapna Patel, RPh, Director of Clinical Services at Mosaic Pharmacy Service, participants will learn how Mosaic Pharmacy Service is improving medication use, health outcomes, and member satisfaction for high-risk members. This session will describe how Mosaic has created a new model for pharmacy care by optimizing regimens for cost, safety, and effectiveness, and will highlight clinical outcomes and case studies that demonstrate benefits to both the health plan and the member.
Chris Bane, VP of Business Development and Marketing, RxAnte
Sapna Patel, RPh, Director of Clinical Services, Mosaic Pharmacy Service
Discover a New Advance in the Treatment of Chemotherapy-Induced Myelosuppression
Sponsored by G1 Therapeutics, Inc.
Join G1 Therapeutics, Inc., a company focused on next-generation cancer therapies, as they review the current management of chemotherapy-induced myelosuppression (CIM). This presentation will highlight a new therapeutic approach to proactively help protect hematopoietic stem and progenitor cells in the bone marrow from chemotherapy-induced damage.
Led by Eric S. Nadler, MD, MPP, the session will outline the burden and current treatment landscape of CIM and present important information about a novel treatment. Mechanism of action, safety and efficacy data, and dosing and administration information will be discussed.
Eric Nadler, MD, MPP, Medical Director, US Oncology HEOR